Thymoma

State of the art

Charles R. Thomas, Cameron D. Wright, Patrick Loehrer

Research output: Contribution to journalArticle

220 Citations (Scopus)

Abstract

Thymoma is the most common tumor of the anterior mediastinum. This tumor is associated with unique paraneoplastic syndromes, such as myasthenia gravis, hypogammaglobulinemia, and pure red cell aplasia. The rarity of this tumor, however, has somewhat obscured the optimal treatment for this disease. For the majority of patients who present with localized tumor, surgical extirpation remains the standard of choice. Adjuvant radiotherapy seems to improve local control and survival. In more advanced disease, systemic therapy has been demonstrated to produce a 50% to 80% objective response rate. These observations have led to the development of multimodality therapy for the treatment of patients with advanced thymoma. In this article, we will review the current perspectives on the management of early stage and advanced thymoma.

Original languageEnglish (US)
Pages (from-to)2280-2289
Number of pages10
JournalJournal of Clinical Oncology
Volume17
Issue number7
StatePublished - 1999

Fingerprint

Thymoma
Neoplasms
Pure Red-Cell Aplasia
Paraneoplastic Syndromes
Agammaglobulinemia
Adjuvant Radiotherapy
Myasthenia Gravis
Mediastinum
Therapeutics
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Thomas, C. R., Wright, C. D., & Loehrer, P. (1999). Thymoma: State of the art. Journal of Clinical Oncology, 17(7), 2280-2289.

Thymoma : State of the art. / Thomas, Charles R.; Wright, Cameron D.; Loehrer, Patrick.

In: Journal of Clinical Oncology, Vol. 17, No. 7, 1999, p. 2280-2289.

Research output: Contribution to journalArticle

Thomas, CR, Wright, CD & Loehrer, P 1999, 'Thymoma: State of the art', Journal of Clinical Oncology, vol. 17, no. 7, pp. 2280-2289.
Thomas CR, Wright CD, Loehrer P. Thymoma: State of the art. Journal of Clinical Oncology. 1999;17(7):2280-2289.
Thomas, Charles R. ; Wright, Cameron D. ; Loehrer, Patrick. / Thymoma : State of the art. In: Journal of Clinical Oncology. 1999 ; Vol. 17, No. 7. pp. 2280-2289.
@article{ce29672e7167490eab2129e683d6f37a,
title = "Thymoma: State of the art",
abstract = "Thymoma is the most common tumor of the anterior mediastinum. This tumor is associated with unique paraneoplastic syndromes, such as myasthenia gravis, hypogammaglobulinemia, and pure red cell aplasia. The rarity of this tumor, however, has somewhat obscured the optimal treatment for this disease. For the majority of patients who present with localized tumor, surgical extirpation remains the standard of choice. Adjuvant radiotherapy seems to improve local control and survival. In more advanced disease, systemic therapy has been demonstrated to produce a 50{\%} to 80{\%} objective response rate. These observations have led to the development of multimodality therapy for the treatment of patients with advanced thymoma. In this article, we will review the current perspectives on the management of early stage and advanced thymoma.",
author = "Thomas, {Charles R.} and Wright, {Cameron D.} and Patrick Loehrer",
year = "1999",
language = "English (US)",
volume = "17",
pages = "2280--2289",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - Thymoma

T2 - State of the art

AU - Thomas, Charles R.

AU - Wright, Cameron D.

AU - Loehrer, Patrick

PY - 1999

Y1 - 1999

N2 - Thymoma is the most common tumor of the anterior mediastinum. This tumor is associated with unique paraneoplastic syndromes, such as myasthenia gravis, hypogammaglobulinemia, and pure red cell aplasia. The rarity of this tumor, however, has somewhat obscured the optimal treatment for this disease. For the majority of patients who present with localized tumor, surgical extirpation remains the standard of choice. Adjuvant radiotherapy seems to improve local control and survival. In more advanced disease, systemic therapy has been demonstrated to produce a 50% to 80% objective response rate. These observations have led to the development of multimodality therapy for the treatment of patients with advanced thymoma. In this article, we will review the current perspectives on the management of early stage and advanced thymoma.

AB - Thymoma is the most common tumor of the anterior mediastinum. This tumor is associated with unique paraneoplastic syndromes, such as myasthenia gravis, hypogammaglobulinemia, and pure red cell aplasia. The rarity of this tumor, however, has somewhat obscured the optimal treatment for this disease. For the majority of patients who present with localized tumor, surgical extirpation remains the standard of choice. Adjuvant radiotherapy seems to improve local control and survival. In more advanced disease, systemic therapy has been demonstrated to produce a 50% to 80% objective response rate. These observations have led to the development of multimodality therapy for the treatment of patients with advanced thymoma. In this article, we will review the current perspectives on the management of early stage and advanced thymoma.

UR - http://www.scopus.com/inward/record.url?scp=0344654871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344654871&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 2280

EP - 2289

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -